WST
HealthcareWest Pharmaceutical Services, Inc. · Medical - Instruments & Supplies · $24B
What is West Pharmaceutical Services, Inc.?
West Pharmaceutical Services is a large-cap healthcare company specializing in containment and delivery systems for injectable drugs, serving pharmaceutical and biotech customers across global markets.
The company operates through two segments: Proprietary Products, which supplies stoppers, seals, syringe components, and self-injection devices to drug manufacturers; and Contract-Manufactured Products, which designs and assembles devices for surgical, diagnostic, and drug delivery applications. Revenue is driven by recurring demand from pharmaceutical and biologic companies that require compliant, high-quality primary packaging.
Founded in 1980 and headquartered in Exton, Pennsylvania, West Pharmaceutical has built decades of expertise in drug packaging infrastructure.
- Injectable drug containment components (stoppers, seals, vials)
- Crystal Zenith cyclic olefin polymer packaging
- Self-injection and drug delivery devices
- Contract-manufactured surgical and diagnostic assemblies
Is WST a Good Stock to Buy?
UQS Score rates WST as Good overall, reflecting a balanced but nuanced profile across its five quality pillars.
The Risk pillar stands out as the strongest element of WST's profile, suggesting the business carries below-average financial and operational vulnerability relative to sector peers. Quality also rates Good, pointing to a fundamentally sound business model.
Growth is the weakest pillar, indicating near-term expansion may be limited, while Moat and Valuation both register as Neutral.
See the full pillar breakdown and detailed financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does WST pay dividends?
Yes — West Pharmaceutical Services, Inc. pays a dividend.
West Pharmaceutical Services pays a regular dividend, which is relatively uncommon among healthcare equipment companies reinvesting heavily in R&D. This reflects the company's stable cash generation and management's commitment to returning capital to shareholders alongside ongoing business investment.
When does WST report earnings?
West Pharmaceutical Services reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's recent results have reflected the broader normalization in pharmaceutical packaging demand following elevated post-pandemic volumes. Revenue trends and margin dynamics are closely watched given the growth headwinds visible in the UQS Growth pillar rating.
For the most recent quarter's results, visit West Pharmaceutical Services' official investor relations page.
WST Price History
-17.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in West Pharmaceutical Services, Inc.?
Based on West Pharmaceutical Services, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does West Pharmaceutical Services do?
West Pharmaceutical Services designs and manufactures containment and delivery systems for injectable drugs. Its products include rubber stoppers, polymer vials, syringe components, and self-injection devices used by pharmaceutical and biotech companies worldwide.
Does WST pay dividends?
Yes, WST pays a regular dividend. This reflects the company's consistent cash generation and its approach to balancing shareholder returns with ongoing capital investment in its manufacturing and product development capabilities.
When does WST report earnings?
West Pharmaceutical Services follows a standard quarterly earnings cadence. For confirmed dates and the most recent financial results, check the investor relations section of the company's official website.
Is WST a good stock to buy?
WST earns a Good UQS Score overall, with particular strength in the Risk pillar and solid Quality ratings. However, the Growth pillar is rated Weak, which may matter depending on your investment horizon. The full pillar breakdown is available to Pro members.
Is WST overvalued?
WST's Valuation pillar is rated Neutral, suggesting the stock is neither clearly cheap nor obviously expensive relative to its fundamentals. Pro members can access the complete valuation metrics behind this assessment.
What is WST's market cap bracket?
West Pharmaceutical Services is classified as a large-cap company, reflecting its established scale within the healthcare packaging and drug delivery systems industry.
Is WST a long-term quality indicator?
From a quality standpoint, WST's Good UQS Score and Strong Risk rating suggest a relatively durable business. However, the Weak Growth pillar is a factor long-term investors should weigh carefully alongside the company's moat and reinvestment trajectory.
What sector does WST belong to?
West Pharmaceutical Services operates in the Healthcare sector, specifically within the medical devices and drug delivery infrastructure space, supplying critical packaging components to pharmaceutical and biologic manufacturers globally.
Unlock Full WST Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Moat, Growth, Risk, and Valuation
- ✓Access complete financial metrics and trend data
- ✓Compare WST against sector peers with side-by-side scoring
- ✓Get the full analyst-grade quality breakdown in one place
Pro Analysis
WST — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | 19.0 | 0.0 | 54.0 | 0.0 | 36.9 | 0.0 | -26.0 |
| Aug 8, 2026 | 45.0 | 44.5 | 54.0 | 16.9 | 98.3 | 15.2 | -12.6 |
| Aug 3, 2026 | 57.6 | 63.1 | 54.0 | 41.1 | 98.3 | 35.8 | -0.1 |
| Jul 25, 2026 | 57.7 | 63.2 | 54.0 | 40.4 | 98.3 | 36.8 | +1.1 |
| Jul 24, 2026 | 56.6 | 62.3 | 54.0 | 39.7 | 98.3 | 32.6 | +0.2 |
| Jul 23, 2026 | 56.4 | 62.2 | 54.0 | 39.6 | 97.3 | 32.2 | 0.0 |
| Jul 22, 2026 | 56.4 | 62.2 | 54.0 | 39.6 | 97.3 | 32.1 | -0.1 |
| Jul 21, 2026 | 56.5 | 62.3 | 54.0 | 39.6 | 97.3 | 33.0 | +0.1 |
| Jul 18, 2026 | 56.4 | 62.2 | 54.0 | 39.6 | 97.3 | 32.2 | +0.1 |
| Jul 17, 2026 | 56.3 | 62.2 | 54.0 | 39.6 | 97.3 | 31.8 | -0.1 |
WST — Pillar Breakdown
Quality
— 0.0/100 (25%)West Pharmaceutical Services, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Ability to convert revenue into operating profit.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)West Pharmaceutical Services, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Analyst consensus for future revenue growth.
Risk
— 36.9/100 (15%)West Pharmaceutical Services, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)West Pharmaceutical Services, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 54/100 (25%)West Pharmaceutical Services, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for WST.
Score Composition
Financial Data
More Stock Analysis
How is the WST UQS Score Calculated?
The UQS (Unified Quality Score) for West Pharmaceutical Services, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses West Pharmaceutical Services, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether West Pharmaceutical Services, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.